Company Analysis
Sign in

Vor Biopharma Inc. (VOR)

Nasdaq: VOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.0
◀ Past 3.5● Present 1.7▶ Future 6.4
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 30, 2026Mar 20, 2025Mar 20, 2024Mar 23, 2023Mar 14, 2022Mar 25, 2021
Research and development321,53293,31094,31564,55047,52931,618
General and administrative50,11027,87531,72128,86821,48911,748
Total operating expenses371,642121,185126,03693,41869,01843,366
Operating income-371,642-121,185-126,036-93,418-69,018-43,366
Interest and investment income5,8684,2718,1731,32411929
Total non-operating income (expense)-324,3394,2718,1731,32411929
Net income including non-controlling interests-695,981-116,914-117,863-92,094-68,899-43,337
Net income-695,981-116,914-117,863-92,094-68,899-43,337
Net income to common shareholders··-117,863-92,094-70,127-49,262
Earnings per share, basic-70.50-34.03r-35.00b-46.60b-42.00b·
Earnings per share, diluted-70.50-34.03r-35.00b-46.60b-42.00b·
Earnings per share, basic and diluted····-42.00b-4,611.40b
Weighted average shares, basic9,871,8663,435,533r3,359,599b1,977,571b1,671,661b·
Weighted average shares, diluted9,871,8663,435,533r3,359,599b1,977,571b1,671,661b·
Weighted average shares, basic and diluted····1,671,661b10,683b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-20 reverse split of Jun 2026.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton VOR · research, not advice